Cargando…

A tri-specific killer engager against mesothelin targets NK cells towards lung cancer

New treatments are required to enhance current therapies for lung cancer. Mesothelin is a surface protein overexpressed in non-small cell lung cancer (NSCLC) that shows promise as an immunotherapeutic target in phase I clinical trials. However, the immunosuppressive environment in NSCLC may limit ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kennedy, Philippa R., Vallera, Daniel A., Ettestad, Brianna, Hallstrom, Caroline, Kodal, Behiye, Todhunter, Deborah A., Bendzick, Laura, Hinderlie, Peter, Walker, Joshua T., Pulkrabek, Brittany, Pastan, Ira, Kratzke, Robert A., Fujioka, Naomi, Miller, Jeffrey S., Felices, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992642/ https://www.ncbi.nlm.nih.gov/pubmed/36911670 http://dx.doi.org/10.3389/fimmu.2023.1060905

Ejemplares similares

NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo
por: Vallera, Daniel A., et al.
Publicado: (2020)

A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer
por: Vallera, Daniel A., et al.
Publicado: (2021)

TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity
por: Kaminski, Michael F, et al.
Publicado: (2022)

Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer
por: Felices, Martin, et al.
Publicado: (2023)

Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion
por: Myers, Jacob A., et al.
Publicado: (2022)

Modulating Mesothelin Shedding to Improve Therapy
por: Zhang, Yujian, et al.
Publicado: (2012)

Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker
por: Schmohl, Joerg U., et al.
Publicado: (2016)

Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line
por: Hollevoet, Kevin, et al.
Publicado: (2015)

Multiple proteases are involved in mesothelin shedding by cancer cells
por: Liu, Xiufen, et al.
Publicado: (2020)

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin
por: Liu, Xiufen, et al.
Publicado: (2022)

Mesothelin, Stereocilin, and Otoancorin are predicted to have superhelical structures with ARM-type repeats
por: Sathyanarayana, Bangalore K, et al.
Publicado: (2009)

Combination Treatments with the PKC Inhibitor, Enzastaurin, Enhance the Cytotoxicity of the Anti-Mesothelin Immunotoxin, SS1P
por: Mattoo, Abid R., et al.
Publicado: (2013)

A trispecific killer engager molecule against CLEC12A effectively induces NK cell mediated killing of AML cells
por: Arvindam, Upasana Sunil, et al.
Publicado: (2020)

Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures
por: Liu, Wenlong, et al.
Publicado: (2022)

Combining anti-CTLA4 with RG7787, an immunotoxin targeting mesothelin, promotes tumor eradication
por: Leshem, Jasmin, et al.
Publicado: (2015)

Structures of Cancer Antigen Mesothelin and Its Complexes with Therapeutic Antibodies
por: Zhan, Jingyu, et al.
Publicado: (2023)

Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity
por: Mazor, Ronit, et al.
Publicado: (2016)

New High Affinity Monoclonal Antibodies Recognize Non-Overlapping Epitopes On Mesothelin For Monitoring And Treating Mesothelioma
por: Zhang, Yi-Fan, et al.
Publicado: (2015)

Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice
por: Zhang, Jingli, et al.
Publicado: (2014)

Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer
por: Cao, Bihui, et al.
Publicado: (2021)

Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer
por: Kennedy, Philippa R., et al.
Publicado: (2022)

ARID5B regulates metabolic programming in human adaptive NK cells
por: Cichocki, Frank, et al.
Publicado: (2018)

Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity
por: Schmohl, Jörg U., et al.
Publicado: (2017)

Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer
por: Inoue, Satoshi, et al.
Publicado: (2020)

High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis
por: Thomas, Anish, et al.
Publicado: (2015)

CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017)

Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development
por: Schmohl, Joerg U., et al.
Publicado: (2015)

Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors
por: Pilbeam, Kristy, et al.
Publicado: (2017)

Liver myofibroblasts of murine origins express mesothelin: Identification of novel rat mesothelin splice variants*
por: Fausther, Michel, et al.
Publicado: (2017)

Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors
por: Gubbels, Jennifer AA, et al.
Publicado: (2006)

Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin
por: Oh, Felix, et al.
Publicado: (2018)

Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors
por: Tomar, Sakshi, et al.
Publicado: (2022)

Safety and biodistribution of (111)In-amatuximab in patients with mesothelin expressing cancers using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging
por: Lindenberg, Liza, et al.
Publicado: (2015)

Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies
por: Schmohl, Joerg U., et al.
Publicado: (2018)

Targeting mesothelin in ovarian cancer
por: Ghafoor, Azam, et al.
Publicado: (2018)

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity
por: Stish, B J, et al.
Publicado: (2009)

Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo
por: Ye, Lin, et al.
Publicado: (2019)

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin
por: Snell, Daniel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9t46n93me6a1op92cjl0jknels